What is the brand name for tirzepatide in the UK?

Why does tirzepatide have a different name in the US?

If you have come across the name Zepbound in articles or on social media, you are not imagining things, it is a real medicine. Zepbound is the US brand name for tirzepatide sold specifically for weight management. Eli Lilly chose to launch the drug under two different trade names depending on the territory and the indication. In the UK, both the weight-management and the type 2 diabetes uses of tirzepatide are authorised under a single name: Mounjaro.

Zepbound does not exist as a UK product. It carries US dosing presentations, US pricing and US regulatory status, none of which apply here. Any seller offering 'Zepbound' in the UK is not supplying a UK-licensed medicine, and the MHRA has warned repeatedly about the risks of buying weight-loss injections through unverified online channels. You can read more about those risks on the tirzepatide brand names page, which covers the full international picture. For UK purposes, Mounjaro is the name to know.

It is worth being clear about one more name that sometimes causes confusion: Rybelsus and Ozempic are brand names for a completely different medicine (semaglutide) and are not related to tirzepatide at all. If you want a full rundown of what tirzepatide is sold as across different markets, the tirzepatide name brands page explains how each name relates to the same underlying molecule. That is understandable.

What does the Mounjaro brand actually tell you about how tirzepatide works?

Mounjaro's mechanism is what sets it apart from every other licensed weight-loss medicine in the UK. It is a dual agonist, meaning it activates two gut-hormone receptors at once: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Most weight-management injectables on the market target GLP-1 alone. Mounjaro targets both, which is why clinicians and researchers have been watching its trial data closely.

Both receptors are involved in appetite regulation and the feeling of fullness after eating. Activating them together slows the rate at which the stomach empties and reduces appetite signals reaching the brain. The result, seen in the SURMOUNT-1 clinical trial published in the New England Journal of Medicine, was an average body-weight reduction of around 20–21% at the 15 mg dose over 72 weeks, figures that were notable at the time. The trial involved thousands of adults without diabetes.

Treatment starts at a low starter dose of 2.5 mg, which is there to give your body time to adjust before moving toward higher doses. The prescriber manages the schedule. Mounjaro comes in six UK strengths: 2.5, 5, 7.5, 10, 12.5 and 15 mg, each delivered via the same pre-filled KwikPen. Detailed dosing and storage information is in the Mounjaro SmPC on the eMC, and a prescriber will walk through what is right for you individually.

Who is Mounjaro licensed to treat, and what does that mean in practice?

The UK licence for Mounjaro (tirzepatide) for weight management covers adults with a BMI of 30 or above, or 27 and above when at least one weight-related health condition is present, for example, high blood pressure, high cholesterol, prediabetes or obstructive sleep apnoea. BMI thresholds are adjusted downward by 2.5 kg/m² for South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds under UK clinical guidance.

NICE recommended tirzepatide in December 2024 (Technology Appraisal 1026) for NHS use in adults with a BMI of 35 or above plus at least one weight-related condition, with phased rollout currently expanding through 2025 and 2026. Private access through a regulated online pharmacy does not require meeting the NHS cohort criteria, but a prescriber still assesses every consultation on its clinical merits, BMI alone does not guarantee a prescription.

If you are curious about how the NHS rollout works alongside the private route, the Mounjaro overview page covers both in detail. For a broader look at all licensed weight-management options, the weight-loss treatments page lays out the landscape. Mounjaro carries a Black Triangle (▼) designation, meaning it is subject to additional MHRA monitoring while post-market safety data continues to accumulate.

Is there an oral version of tirzepatide, and does it have its own brand name?

As of mid-2026, there is no oral tirzepatide licensed anywhere in the world. The only approved form is the once-weekly subcutaneous injection, sold as Mounjaro in the UK. Oral tirzepatide is in clinical development, but no brand name has been announced for a UK product and no approval has been granted by the MHRA.

The oral GLP-1 medicine that has recently received UK approval is Wegovy tablets, oral semaglutide, not tirzepatide. Those two are different molecules, different mechanisms and different brand names. If a source is describing an oral tirzepatide brand name as though it already exists in the UK, that information is not yet accurate. Checking the tirzepatide brand page or the tirzepatide generic and brand information page will help keep the picture current as guidance develops, and the tirzepatide brands page is a useful companion if you want to compare every commercial name that has been used for this medicine across different countries and indications.

For now, if a prescriber recommends tirzepatide for weight management in the UK, Mounjaro is the product they are prescribing. If you would like a clinician to assess whether it is appropriate for you, the team at nume carries out a same-day clinical review, a real prescriber reads your consultation, not a piece of software. You can start that process, at no cost, whenever you are ready.